INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 222 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $475 | +101.3% | 25,642 | +45.6% | 0.05% | +88.0% |
| Q1 2023 | $236 | -99.9% | 17,609 | -10.4% | 0.02% | 0.0% |
| Q3 2022 | $274,000 | -0.4% | 19,656 | +64.9% | 0.02% | +31.6% |
| Q1 2021 | $275,000 | +12.2% | 11,921 | +20.3% | 0.02% | -26.9% |
| Q4 2020 | $245,000 | -79.6% | 9,911 | -60.4% | 0.03% | -81.3% |
| Q2 2020 | $1,199,000 | +391.4% | 25,025 | +580.0% | 0.14% | +631.6% |
| Q3 2019 | $244,000 | -32.0% | 3,680 | +14.7% | 0.02% | -5.0% |
| Q1 2019 | $359,000 | -33.3% | 3,209 | -39.9% | 0.02% | -31.0% |
| Q4 2018 | $538,000 | +142.3% | 5,342 | +101.5% | 0.03% | +190.0% |
| Q2 2018 | $222,000 | -5.1% | 2,651 | -33.8% | 0.01% | -16.7% |
| Q4 2017 | $234,000 | -33.5% | 4,003 | +174.7% | 0.01% | -61.3% |
| Q2 2015 | $352,000 | – | 1,457 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
| Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
| BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
| ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
| FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
| Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
| NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |